Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SILO
Silo Pharma, Inc. (SILO) EV/Sales
As of 16 October 2026, Silo Pharma, Inc. (SILO) trades at a EV/Sales of −54.6×. Over the past ten years it has ranged from −118× (September 2022) to 52,875× (December 2020); the current reading is higher than 11% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −55.6× | — |
| FY2024 | −52.8× | — |
| FY2023 | −41.4× | — |
| FY2022 | −60.4× | — |
| FY2021 | 46.7× | — |
| FY2019 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2026 | −15.2× | — |
| Dec 2025 | −55.6× | — |
| Sep 2025 | 8.0× | — |
| Jun 2025 | −31.9× | — |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SILO Silo Pharma, Inc. | −54.6× |
| BRTX Biorestorative Therapies, Inc. compare | −5.7× |
| CLSDQ Clearside Biomedical, Inc. compare | −1.2× |
| GNPX GENPREX compare | n/m |
| PPBT Purple Biotech Ltd. Sponsored ADR compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. compare | 3.6× |
| TRVN Trevena, Inc. compare | 35.0× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)